Pharmaceutical News

RSS

ST Asia signs licensing deal with PharmaMar to distribute new multiple myeloma drug in South East Asia

International biopharmaceutical company Specialised Therapeutics Asia will supply and distribute a novel oncology drug candidate throughout South East Asia, following an exclusive licensing deal with European pharmaceutical company PharmaMar.

3 Feb 2016

FDA approves ZEMBRACESymTouch (sumatriptan succinate) injection for treatment of acute migraines

Dr. Reddy's Laboratories, announced today that the U.S. Food and Drug Administration has approved ZEMBRACESymTouch (sumatriptan succinate) injection, a drug-device combination product intended for the treatment of acute migraine episodes, with or without aura, in adults who are inadequately managed with existing treatment regimens.

3 Feb 2016

Lupin Pharmaceuticals releases Metformin HCl ER Tablets

Pharma Major Lupin Limited announced today that its US subsidiary, Lupin Pharmaceuticals Inc., has launched its Metformin HCl ER Tablets, 500 mg and 1000 mg to market a generic equivalent of Santarus Inc.'s Glumetza HCl ER Tablets, 500 mg and 1000 mg.

2 Feb 2016

HUYA, Eisai sign exclusive license agreement for HBI-8000 in Japan and other Asian countries

HUYA Bioscience International President, CEO, Executive Chairman & Founder Dr. Mireille Gillings announced that Eisai Co., Ltd. has acquired from HUYA an exclusive license agreement for HBI-8000 in Japan, South Korea, Thailand, Malaysia, Indonesia, Philippines, Vietnam and Singapore.

1 Feb 2016

International Aspirin Foundation seeks applicants for Senior Science Award 2016

The International Aspirin Foundation, founded in 1974, is seeking applicants for the Senior Science Award 2016. This is open to scientists who can demonstrate a track record of valuable, significant medical scientific research (basic, translational or clinical), contributing to the scientific knowledge of aspirin/acetylsalicylic acid.

31 Jan 2016

Study provides vital information about mechanisms governing DNA repair

DNA damage can lead to gene inactivation or deregulation and cause various diseases such as cancer; however, many DNA repair mechanisms allow cells to survive against such damage. A study lead by Antoine Simoneau of the laboratory of Dr. Hugo Wurtele, a researcher in immunology-oncology at the Maisonneuve-Rosemont Hospital (CIUSS de l'Est-de-l'Île-de-Montréal) and professor at the Faculty of Medicine, University of Montreal, and recently published in the prestigious journal Nucleic Acids Research, provides valuable information about certain mechanisms governing DNA repair.

31 Jan 2016

COG presents plan to effectively handle future pediatric cancer drug shortages

The Children's Oncology Group has taken steps to help pediatric oncologists across the United States plan for the next shortage of life-saving chemotherapy drugs used for children with cancer. The COG is the world's largest organization devoted exclusively to childhood and adolescent cancer research and is supported in part by the St. Baldrick's Foundation, the largest private funder of childhood cancer research grants.

31 Jan 2016

U of M's 'Ask About Aspirin' initiative aims to reduce incidence of first heart attack or stroke

Cardiovascular diseases are the leading causes of death and disability in the United States, accounting for nearly one-third of all deaths. The diseases also create an immense national health economic burden.

30 Jan 2016

FDA-approved blood pressure drug reduces cell damage linked to Alzheimer's disease

In laboratory neuronal cultures, an FDA-approved drug used to treat high blood pressure reduced cell damage often linked to Alzheimer's disease, say researchers at Georgetown University Medical Center and the National Institutes of Health.

30 Jan 2016

Sphingosine kinase inhibitor slows castration-resistant prostate cancer cell growth

A first-in-class sphingosine kinase 2 inhibitor slowed the growth of castration-resistant prostate cancer cells, in part by inhibiting the enzyme dihydroceramide desaturase (DEGS), but did not kill them, according to the results of preclinical in vitro and in vivo studies published in the December 2015 issue of Molecular Cancer Therapeutics by researchers at the Medical University of South Carolina and others.

30 Jan 2016

EC approves expanded use of Daklinza (daclatasvir) for patients with chronic HCV and HIV co-infection

Bristol-Myers Squibb today announced that the European Commission has approved the expanded use of Daklinza, a first-in-class oral, once-a-day pill used in combination with other treatments as an option for adult patients with chronic hepatitis C virus infection who are co-infected with HIV or who have had a prior liver transplant.

30 Jan 2016

Allergan and AstraZeneca partner to develop, commercialize ATM-AVI for MBL-producing pathogens

Allergan plc today announced that it has entered into a global agreement with AstraZeneca to develop and commercialize ATM-AVI, an investigational, fixed-dose antibiotic combining aztreonam and avibactam.

30 Jan 2016

Allergan's investigational medication rapastinel granted FDA Breakthrough Therapy designation

Allergan plc., a leading global pharmaceutical company today announced that its Phase III ready investigational medication rapastinel (GLYX-13) received Breakthrough Therapy designation from the U.S. Food and Drug Administration for adjunctive treatment of Major Depressive Disorder (MDD).

29 Jan 2016

Eisai's Halaven receives FDA approval for treatment of patients with metastatic liposarcoma

Eisai Inc. announced today that the U.S. Food and Drug Administration approved Halaven (eribulin mesylate) Injection (0.5 mg per mL) for the treatment of patients with unresectable or metastatic liposarcoma who have received a prior anthracycline-containing regimen.

29 Jan 2016

Access for new melanoma treatment remains uncertain for patients despite UK launch

Novartis announced today that Tafinlar (dabrafenib) + Mekinist (trametinib), the first oral combination therapy to be licensed for advanced melanoma, is now available in the UK for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.

29 Jan 2016

Researchers develop new painkiller as strong as morphine but not addictive

Researchers at Tulane University and Southeast Louisiana Veterans Health Care System have developed a painkiller that is as strong as morphine but isn't likely to be addictive and with fewer side effects, according to a new study in the journal Neuropharmacology.

29 Jan 2016

Pharmaceutical News

ST Asia signs licensing deal with PharmaMar to distribute new multiple myeloma drug in South East Asia

FDA approves ZEMBRACESymTouch (sumatriptan succinate) injection for treatment of acute migraines

Lupin Pharmaceuticals releases Metformin HCl ER Tablets

HUYA, Eisai sign exclusive license agreement for HBI-8000 in Japan and other Asian countries

International Aspirin Foundation seeks applicants for Senior Science Award 2016

Study provides vital information about mechanisms governing DNA repair

COG presents plan to effectively handle future pediatric cancer drug shortages

U of M's 'Ask About Aspirin' initiative aims to reduce incidence of first heart attack or stroke

FDA-approved blood pressure drug reduces cell damage linked to Alzheimer's disease

Sphingosine kinase inhibitor slows castration-resistant prostate cancer cell growth

EC approves expanded use of Daklinza (daclatasvir) for patients with chronic HCV and HIV co-infection

Allergan and AstraZeneca partner to develop, commercialize ATM-AVI for MBL-producing pathogens

Allergan's investigational medication rapastinel granted FDA Breakthrough Therapy designation

Eisai's Halaven receives FDA approval for treatment of patients with metastatic liposarcoma

Access for new melanoma treatment remains uncertain for patients despite UK launch

Researchers develop new painkiller as strong as morphine but not addictive

Anticholinergic medications may not be best option for dementia patients in rehab facility

Vitabiotics introduces new Wellkid Multi-vitamin liquid for kids

New blood clotting analysis system could help determine effects antithrombotic (anti-clotting) drugs

Zepatier receives FDA approval for treatment of chronic HCV genotypes 1 and 4 infections

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News